PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR
Cell Proliferation · 2026
DOI: 10.1111/cpr.70086 ↗At a glance
Journal article in Cell Proliferation, 2026. Written by Miao Wang and 11 co-authors. Institution: Zhejiang Key Laboratory of Medical Epigenetics, Zhejiang Key Laboratory of Aging and Cancer Biology, Hangzhou Normal University School of Basic Medic…. Major MEDLINE topics: Drug Resistance, Neoplasm, Melanoma, ErbB Receptors, Skin Neoplasms. Cited 5 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Interdisciplinary Research Project of Hangzhou Normal University, Zhejiang Provincial Department of Science and Technology, National Natural Science Foundation of China.
Abstract (original language)
Melanoma is the most serious type of skin cancer. About half of all melanomas have activating BRAF mutations. Targeted therapy for malignant melanoma with BRAF inhibitor (BRAFi) or its combination with MEK inhibitor (MEKi) improves the clinical outcomes of patients, but resistance develops invariably. The underlying mechanisms remain incompletely understood. Here, we show that caveolae number is increased in both BRAFi and BRAFi + MEKi‐resistant melanoma cells, and the expression of the critical caveolae component PTRF is significantly upregulated in drug‐resistant melanoma cell lines and tumour tissues. Knockdown of PTRF in drug‐resistant cells reduces proliferation with increased apoptosis, whereas ectopic expression of PTRF confers resistance on parental cells to BRAFi or BRAFi + MEKi. On the contrary, the knockdown of PTRF in parental cells reduces their ability to acquire drug resistance induced by BRAFi treatment. Interestingly, we find that the expression of EGFR is increased along with PTRF and caveolin‐1 in drug‐resistant cells and in PTRF transduced parental cells, whereas knockdown of PTRF results in down‐regulation of EGFR expression and attenuates drug resistance of parental cells induced by PTRF expression. Together, these results suggest that PTRF contributes to therapy resistance through upregulating EGFR in melanoma cells.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Zhejiang Key Laboratory of Medical Epigenetics, Zhejiang Key Laboratory of Aging and Cancer Biology, Hangzhou Normal University School of Basic Medical Sciences, Hangzhou, China.
- State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research of Gastrointestinal Cancer, The Second Affiliated Hospital, University of South China, Hengyang, China.
ORCID profiles: Jian Mao, Yu-Sheng Cong
Funding
- Interdisciplinary Research Project of Hangzhou Normal University
- Zhejiang Provincial Department of Science and Technology
- National Natural Science Foundation of China
Cite
APA
Wang, M., Cao, Y., Ren, C., Wang, K., Wang, Y., Wu, X., Mao, J., Liang, Q., Zhang, Q., Lu, H., Xu, X., & Cong, Y. S. (2026). PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR. Cell Proliferation. https://doi.org/10.1111/cpr.70086
Vancouver
Wang M, Cao Y, Ren C, Wang K, Wang Y, Wu X, et al. PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR. Cell Proliferation. 2026. doi:10.1111/cpr.70086
BibTeX
@article{Wang2026,
author = {Wang, Miao and Cao, Ying and Ren, Chengcheng and Wang, Ke and Wang, Yaxiang and Wu, Xiaoying and Mao, Jian and Liang, Qian and Zhang, Qian and Lu, Hezhe and Xu, Xiaowei and Cong, Yu-Sheng},
title = {PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR},
journal = {Cell Proliferation},
year = {2026},
doi = {10.1111/cpr.70086}
}
EUVIMED